Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease
Public ClinicalTrials.gov record NCT00349752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease. Subjects had to be in remission (CDAI\<=150) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.
Study identification
- NCT ID
- NCT00349752
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 174 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Jun 30, 2009
- Completion
- Jun 30, 2009
- Last update posted
- Aug 8, 2018
2006 – 2009
United States locations
- U.S. sites
- 54
- U.S. states
- 29
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Montgomery | Alabama | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Oceanside | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | Palo Alto | California | — | — |
| Not listed | Roseville | California | — | — |
| Not listed | Golden | Colorado | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | North Miami Beach | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Savannah | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Bloomington | Indiana | — | — |
| Not listed | Topeka | Kansas | — | — |
| Not listed | Bowling Green | Kentucky | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Metairie | Louisiana | — | — |
| Not listed | Annapolis | Maryland | — | — |
| Not listed | Newton | Massachusetts | — | — |
| Not listed | Chesterfield | Michigan | — | — |
| Not listed | Dearborn | Michigan | — | — |
| Not listed | Troy | Michigan | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Ocean Springs | Mississippi | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Mexico | Missouri | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Germantown | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Burlington | Vermont | — | — |
| Not listed | Chesapeake | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Madison | Wisconsin | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
| Not listed | Monroe | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00349752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 8, 2018 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00349752 live on ClinicalTrials.gov.